Disease trajectories and mortality among women diagnosed with breast cancer

[1]  A. Jemal,et al.  Annual Report to the Nation on the Status of Cancer, Part 2: Patient Economic Burden Associated With Cancer Care , 2021, Journal of the National Cancer Institute.

[2]  Ferran Sanz,et al.  Identifying temporal patterns in patient disease trajectories using dynamic time warping: A population-based study , 2018, Scientific Reports.

[3]  J. Ludvigsson,et al.  The Swedish cause of death register , 2017, European Journal of Epidemiology.

[4]  K. Czene,et al.  Time‐dependent risk of depression, anxiety, and stress‐related disorders in patients with invasive and in situ breast cancer , 2017, International journal of cancer.

[5]  K. Czene,et al.  Time‐dependent risk and predictors of venous thromboembolism in breast cancer patients: A population‐based cohort study , 2017, Cancer.

[6]  M. Lacouture,et al.  Dermatological adverse events with taxane chemotherapy , 2016, European Journal of Dermatology.

[7]  K. Czene,et al.  Infection-related hospitalizations in breast cancer patients: Risk and impact on prognosis. , 2016, The Journal of infection.

[8]  R. Chlebowski,et al.  Aromatase inhibitors, tamoxifen, and endometrial cancer in breast cancer survivors , 2015, Cancer.

[9]  Tudor I. Oprea,et al.  Temporal disease trajectories condensed from population-wide registry data covering 6.2 million patients , 2014, Nature Communications.

[10]  A. Jemal,et al.  Annual Report to the Nation on the status of cancer, 1975‐2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer , 2014, Cancer.

[11]  T. Lash,et al.  Comprehensive evaluation of the incidence of late effects in 5-year survivors of breast cancer , 2014, Breast Cancer Research and Treatment.

[12]  K. Hemminki,et al.  Effect of autoimmune diseases on risk and survival in female cancers. , 2012, Gynecologic oncology.

[13]  K. Hemminki,et al.  Death causes in breast cancer patients. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  C. O’Malley,et al.  An observational study of the prevalence and incidence of comorbid conditions in older women with breast cancer , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  J. Ludvigsson,et al.  External review and validation of the Swedish national inpatient register , 2011, BMC public health.

[16]  A. Trentham-Dietz,et al.  Use of antidepressants and NSAIDs in relation to mortality in long‐term breast cancer survivors , 2011, Pharmacoepidemiology and drug safety.

[17]  P. Musonda,et al.  Predicting the risk of endometrial cancer in postmenopausal women presenting with vaginal bleeding: the Norwich DEFAB risk assessment tool , 2010, British Journal of Cancer.

[18]  R. Westerling,et al.  Unexplained differences between hospital and mortality data indicated mistakes in death certification: an investigation of 1,094 deaths in Sweden during 1995. , 2009, Journal of clinical epidemiology.

[19]  J. Farley,et al.  Complications of gynecologic surgery. , 2008, The Surgical clinics of North America.

[20]  N. Takai,et al.  Tumorigenic Effects of Tamoxifen on the Female Genital Tract , 2008, Clinical medicine. Pathology.

[21]  J. Goodwin,et al.  Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  K. Czene,et al.  Family history of breast cancer and young age at diagnosis of breast cancer increase risk of second primary malignancies in women: a population-based cohort study , 2006, British Journal of Cancer.

[23]  A James O'Malley,et al.  Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. , 2006, Journal of the National Cancer Institute.

[24]  J. Olsen,et al.  Risk of second cancer among women with breast cancer , 2006, International journal of cancer.

[25]  J. Klijn,et al.  Cause-specific mortality in long-term survivors of breast cancer: A 25-year follow-up study. , 2006, International journal of radiation oncology, biology, physics.

[26]  K. Czene,et al.  Ionizing radiation and tobacco use increases the risk of a subsequent lung carcinoma in women with breast cancer: case-only design. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  L. Kishon-Rabin,et al.  Association Between Birth Control Pills and Voice Quality , 2004, The Laryngoscope.

[28]  K. Hemminki,et al.  Second primary neoplasms in 633,964 cancer patients in Sweden, 1958–1996 , 2001, International journal of cancer.

[29]  C. Shapiro,et al.  Side effects of adjuvant treatment of breast cancer. , 2001, The New England journal of medicine.

[30]  H. Hollema,et al.  TAMOXIFEN TREATMENT AND GYNECOLOGIC SIDE EFFECTS: A REVIEW , 2001, Obstetrics and gynecology.

[31]  Mike Clarke,et al.  Tamoxifen for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[32]  E. Palmer,et al.  Pain as an Indicator of Bone Metastasis , 1988, Acta radiologica.

[33]  A. Jemal,et al.  Breast cancer statistics, 2015: Convergence of incidence rates between black and white women , 2016, CA: a cancer journal for clinicians.

[34]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[35]  S. Mor-Yosef,et al.  Ovarian cysts in premenopausal and postmenopausal tamoxifen-treated women with breast cancer. , 1996, American journal of obstetrics and gynecology.

[36]  T. Möller,et al.  Validity of breast cancer registration from one hospital into the Swedish National Cancer Registry 1971-1991. , 1995, Acta oncologica.